poisar

Stocks · News reference

Cullinan Therapeutics Zipalertinib Combo Clears Key Phase 3 Hurdle As First-Line Lung Cancer Treatment Option Takes Shape

Aug 13, 2026, 3:21 PMVandana Singh

Cullinan Therapeutics and Taiho report positive Phase 3 trial results for zipalertinib in treating advanced lung cancer.

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

AZNCGEMJNJ
Source
benzinga
Observed
Aug 13, 2026, 3:21 PM
Checked
Aug 13, 2026, 3:21 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Aug 27, 2026, 4:11 PMNa

    SMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer Study

    Summit Therapeutics' partner Akeso announced positive phase III HARMONi-GI1 study results showing ivonescimab plus chemotherapy achieved superior overall survival compared to AstraZeneca's Imfinzi plus chemotherapy in advanced biliary tract cancer patients. The drug also met key secondary endpoints for progression-free survival and objective response rate. These results strengthen ivonescimab's development case beyond its initial NSCLC focus into colorectal and genitourinary cancers.

    Read original at zacks-investment-research
    SMMTAZNMRK
  5. Aug 19, 2026, 4:11 PMBenzinga Newsdesk

    Taiho Oncology And Cullinan Therapeutics Say Results From Planned Interim Analysis Of Phase 3 REZILIENT3 Trial Selected For Presentation In Presidential Symposium 2 At IASLC 2026 World Conference On Lung Cancer

    Presentation will feature results from the planned interim analysis of the Phase 3 REZILIENT3 trial, which met its primary endpoint of progression-free survival in first line EGFR exon 20 insertion mutation NSCLCTaiho

    Read original at benzinga
    CGEM